
Supplements and Featured Publications
- Emerging Trends and Formulary Considerations for Atypical Antipsychotics
- Volume 11
- Issue 8 Suppl
Participating Faculty
The American Journal of Managed Care
This supplement to contains information on atypical antipsychotics and their cost effectiveness in the treatment of schizophrenia and bipolar disease.
Faculty
David J. Harrison, PhDSenior Manager
Pfizer Inc
Senior Director
New York, NY
Amie T. Joyce, MPH
PharMetrics, Inc
Medical Director
New York, NY
Michael B. Lustik, MS
Science Applications International Corporation
Director
New York, NY
Daniel A. Ollendorf, MPH
Analytic & Consulting Services
Watertown, MA
George M. Simpson, MD
Department of Psychiatry and the Behavioral Sciences
Los Angeles, CA
Richard C. Surles, PhD
Comprehensive NeuroScience, Inc
Senior Statistician
Reston, VA
Disclosure Statement
The American Journal of Managed Care
It is the policy of to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.
The following participants have declared the following affiliations with corporate organizations:
- David J. Harrison, PhD Employee: Pfizer Inc
Robin P. Hertz, PhD
Employee:
- Pfizer Inc
- Amie T. Joyce, MPH Research Support: Pfizer Inc
Antony D. Loebel, MD
Employee:
- Pfizer Inc
- Michael B. Lustik, MS Contractor: Pfizer Inc
Margaret McDonald, PhD
Employee:
- Pfizer Inc
- Daniel A. Ollendorf, MPH Research Support: Pfizer Inc
George M. Simpson, MD
Consultant:
- Pfizer
Research Support:
- AstraZeneca
- Janssen Pfizer
Richard C. Surles, PhD
Adviser:
- Eli Lilly and Company
- Alan N. Unger, PhD Contractor: Pfizer Inc
The American Journal of Managed Care,
Signed disclosures are on file at the offices of Jamesburg, New Jersey.
This supplement was funded by Pfizer Inc.
Acknowledgments
We would like to thank Laura Brasseur and Debbie Godfrey for their contributions to this supplement.
The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
Articles in this issue
about 20 years ago
Healthcare Spending Among Community-dwelling Adults With Schizophreniaabout 20 years ago
Atypical Antipsychotics and the Burden of Diseaseabout 20 years ago
Impact of Atypical Antipsychotics on Outcomes of Care in Schizophreniaabout 20 years ago
Atypical Antipsychotics: Considerations for Medicaid CoverageNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.